Save the date:
Regional Academic Drug Discovery Symposium
Tomorrow’s Drugs Today
Wednesday November 8, 2017
Location:
Institute for Life Science Entrepreneurship
NJCSTM Building, Kean University
1075 Morris Avenue
Union, NJ 07083

0845 Welcome

0900 Session 1: Different Models

0900 Tri-I TDI/Bridge Medicines: a novel academic drug discovery and development model
Bruce R. Conway, Ph.D.
Director, Rockefeller University and the Tri-Institutional Therapeutic Discovery Institute
Bruce Conway is the Director of the Robertson Therapeutic Development Fund at Rockefeller University. He is also a member of the SAB for the Tri-Institutional Therapeutic Discovery Institute, a collaboration among MSKCC, The Rockefeller University, Weill Cornell Medicine and Takeda, to advance the groundbreaking discoveries of the academic institutions. Bruce earned his PhD in Pharmacology at the Medical College of Virginia and completed his postdoctoral fellowship at the University of Massachusetts Medical Center. He then joined Johnson & Johnson Pharmaceutical Research and Development where he championed the progression of three compounds into the clinic, one of which resulted in the FDA approval of a novel, first-in-class treatment for type 2 diabetes Invokana®. In 2006, he moved to the Institutes for Pharmaceutical Discovery as the Senior Director of Biology where he oversaw the day-to-day operations of the Biology, Pharmacology and DMPK teams. In 2013, Dr. Conway transitioned to academia and served as the “Executive-in-Residence” at Columbia University. The following year, Dr. Conway joined the Rockefeller University where he serves in his current position. He serves on the Faculty within the Clinical Center for Translational Science and as an advisor to Pfizer’s Center for Therapeutic Innovation, Columbia Technology Ventures, the Coulter Translational Research Boot Camp and 1st Pitch Life Sciences NYC.

0925 The Moulder Center for Drug Discovery Research - Integrating the Best of Academia and Industry
Wayne Childers, Ph.D.
Associate Professor, Temple University School of Pharmacy and The Moulder Center for Drug Discovery Research
Wayne Childers is Associate Professor of Medicinal Chemistry at Temple University School of Pharmacy, Philadelphia, PA and Associate Director of the Moulder Center for Drug Discovery Research. Wayne received his BA from Vanderbilt University in chemistry in 1979 and a PhD in organic chemistry from the University of Georgia in 1984. He served as an Assistant Adjunct Professor at Bucknell University before accepting a position as a postdoctoral fellow at the Johns Hopkins University School of Medicine. He then joined Wyeth Research, Inc.in 1987, working for over 23 years as a medicinal chemist in numerous therapeutic areas, including psychiatric diseases, stroke, epilepsy, Alzheimer's disease, and the treatment of chronic pain. Teams under his leadership delivered 4 compounds to clinical trials. Wayne then accepted his present position at Temple University in 2010. Wayne is an author on over 50 peer reviewed papers, reviews and book chapters and is an inventor on 40 US patents.

0950 Bootstrapping Translational Research in Academia – Rutgers University Experience
David Kimball, Ph.D.
Associate Vice President, Research Commercialization, Rutgers University
David Kimball, PhD, is Associate Vice President of Rutgers Translational Sciences and Research Commercialization, in the Office of Research and Economic Development. He is also a Research Professor in the Ernest Mario School of Pharmacy. David obtained his PhD in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook, and spent the first 19 years of his career at Bristol-Myers Squibb Pharmaceutical Research Institute, leading drug discovery and development efforts in cardiovascular medicine and oncology. In 2001 he moved to Lexicon Pharmaceuticals in Princeton, NJ as Vice President of Chemistry and directed discovery and development efforts for Lexicon’s entire small molecule clinical pipeline. Prior to joining Rutgers University, David also served as Senior Vice President of Nonclinical Research at Pharmacopecia, Inc., and Chief Scientific Officer of Hydra Biosciences, in Cambridge, MA.

1015 Additional speaker to be confirmed
Session 2: Funding Translational Research

Ordinarily, academic funding is difficult to obtain for other than basic research. To fund advanced efforts and move down the path to IND, support from groups such as VCs, angel investors, foundations or pharma/biotech needs to be obtained. Understanding what each of these groups are looking for and when might be a good time to approach them will be helpful. This session will be conducted in panel format to maximize utility to the audience using Q&As. The start of the session will be a short introduction from each the 4 panelists representing VC, angel, pharma and foundation.

Session chair – David Kimball, PhD.
Venture Capital firm (to be confirmed)
Stephen Goodman, JD, Co-Founder, Mid-Atlantic Bio Angels
James Golubieski, President, NJ Health Foundation/Foundation Venture Capital Group
Carolyn Buser-Doepner, Ph.D., VP and Global Head of Discovery Partnerships with Academia, Glaxo Smith Kline R&D

Session 3: Case Studies

1400  Trigriluzole: An SBIR-Derived Clinical Compound for the Treatment of Ataxia and Melanoma

Allen Reitz, Ph.D.
CEO, Fox Chase Chemical Diversity Center
Dr. Reitz is CEO and founder of the Fox Chase Chemical Diversity Center, Inc. (www.fc-cdci.com) with laboratories in Doylestown and King of Prussia, PA. FCCDC is an early-stage translational research organization with a core competency in target validation, hit to lead and lead optimization medicinal chemistry. He has had >35 years of experience in the pharmaceutical industry, including nearly 26 years with Johnson & Johnson. He has developed 8 compounds that have entered human clinical trials. He has >140 scientific publications and 61 issued U.S. patents, and is the Editor-in-Chief of the journal Current Topics in Medicinal Chemistry. He has extensive experience in project and portfolio management, target validation, hit triage, hit to lead and lead optimization medicinal chemistry, eADME profiling, and preclinical candidate selection. He is also Adjunct Professor at Drexel University College of Medicine, holds an Executive Masters in Technology Management from the University of Pennsylvania (Wharton, Penn Engineering), and is a Moore Fellow in the Management of Technology (U. Penn.). Dr. Reitz is also a founder and CEO of ALS Biopharma, LLC, focusing on the neurological condition of amyotrophic lateral sclerosis.

1430  CX3CR1 Chemokine Antagonists Halt Metastatic Spreading in Animal Models of Metastasis

Joseph Salvino, Ph.D.
Professor, Medicinal Chemistry, The Wistar Institute
Joe Salvino received his Ph. D. from Brown University with Prof. Paul G. Williard and Postdoc’ed with Professors KC Nicolaou and Ralph F. Hirschmann at the University of Pennsylvania. His expertise in medicinal chemistry, with over twenty years experience. He is currently focusing on early stage in vivo pharmacological target validation, hit to lead, and lead optimization to provide value to Academic Drug Discovery programs. Joe has been involved in three start-up companies: Alliance Discovery, Inc, Kerberos Biopharmaceuticals, Inc, and Context Therapeutics, Inc. the latter two spun out of Drexel University College of Medicine. Joe has a Project leader role in several pharmaceutical companies, successfully optimizing and providing development candidates, several of these candidates have successfully completed human phase I and phase II clinical trials, including Entereg®, ADL-101, and Radezolid®. Expertise: High Throughput Chemistry/ Hit to Lead/ Lead Optimization Medicinal Chemistry / Rational Drug Design.

1500  Additional speaker to be confirmed

Acknowledgements: Models: Bruce Conway, Marlene Jacobson, Joe Salvino; Funding: Brad Sherbourne, Vincent Smeraglia; Posters: David Augeri, Jacques Roberge; Case Studies: Andrew Kruegel; And the wider organizational committee: Bob DeVita, Peter Tolias, Allen Reitz, Dennis Gross, Diane Fabel, Troy Messick, Ofra Weinberger, Keith Bostian, Eric Eckland, Ajay Kumar, Bill Greenlee, John Siekierka, Ron Doll, Nadim Shohdy, Dirk Trauner, Alan Whitehead, Jim Barrett, Amjad Ali, David Bleakman, Mike Foley, Orin Herskowitz, Fraser Glickman, Harvey Homan, Craig Parish, Mike Tocci, Tony delCampo, Steve Lesiak,